講演・口頭発表等 - 中川　美奈

21. Mina Nakagawa. HCC occurrence/recurrence after HCV eradication. APASL STC 2019 2019.04.18

22. Miyako Murakawa, Yasuhiro Asahina, Emi Inoue, Mina Nakagawa, Jun Tuchiya, Ayako Sato, Masato Miyoshi, Tomoyuki Tsunoda, Fukiko Kitahata-Kawai, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Mamoru Watanabe. The association of serum IFN-lambda 3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents . EASL, The International Liver Congress 2019 2019.04.13 Vienna （Austria）

23. MIna Nakagawa, Yasuhiro Asahina, Jun Tsuchiya, Ayako Sato, Tomoyuki Tsunoda, Msato Miyosh, Emi Inoue, Fukiko Kawai-Kitahata, MIyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Makoto Tomita, Mamoru Watanabe. Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients. EASL, The International Liver Congress 2019 2019.04.13 Messe Wien Congress and Exhibition Center(Vienna （Austria）)

24. Mina Nakagawa, Yasuhiro Asahina, Jun Tsuchiya, Ayako Sato, Tomoyuki Tsunoda, Masato Miyoshi, Emi Inoue-Shinomiya, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Makoto Tomita, Mamoru Watanabe. Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients. the EASL scientific programme committee of The International Liver Congress 2019 2019.04.11

25. Nitta S, Kato T, Tuchiya J, Sato A, Tsunoda T, Miyoshi M, Inoue- Shinomiya E, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Asahina Y. The Characteristic and the Anti-HCV Reagents Susceptibility Analysis of NS5A Resistance-Associated Substitutions (RAS) Detected after Daa Treatment Failure Patients. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA）

26. Nakagawa M, Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tomita M, Watanabe M. Post-Treatment M2BPGi Level Is Useful for Predicting HCC Occurrence and Recurrence after Viral Eradication in Chronic Hepatitis C Patients. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA）

27. Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Nakagawa M, Kakinuma S, Watanabe M. Gene Mutational Profile and Viral Integration in Hepatocellular Carcinoma with or without HBV/HCV Suppression. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA）

28. Nitta S, Kato T, Tuchiya J, Shinomiya-Inoue E, Sato A, Tsunoda T, Miyoshi M, Kitahata-Kawai F, Murakawa M, Istui Y, Azuma S, Nakagawa M, Kakinuma S, Asahina Y. The in vitro analysis of NS5A resistance-associated substitutions (RAS) observed in DAA treatment failure patients. 25th International Symposium on Hepatitis C Virus and Related Viruses 2018.10.09 Dublin（Ireland）

29. Mina Nakagawa. Post-treatment M2BPGi level is useful for predicting the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Asian Pacific Association for the Study of the Liver Single Topic Conference (APASL STC) 2018.05.11

30. Kitahata-kawai F, Asahina Y, KakinumaS, Murakawa M, Nitta S, Nagata H, Kaneko S, Inoue E, Miyoshi M, Tsunoda T, Sato A, Nakagawa M, Itsui Y, Azuma S, Tanaka S, Tanabe M, Maekawa S, Enomoto N and Watanabe M. Difference of gene mutational profile among viral- and non-viral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/A AV integration. EASL, The International Liver Congress 2018 2018.04.14 Paris（France）

31. Nakagawa M, Asahina Y, Nagata H, Kaneko S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Watanabe M. Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs - propensity score-matched analysis of a prospective database -. AASLD, The Liver Meeting 2017 2017.10.22 Walter E. Washington Convention Center（Washington D.C, USA）

32. Shun Kaneko, Sei Kakinuma, Yasuhiro Asahina, Akihide Kamiya, Masato Miyoshi, Tomoyuki Tsunoda, Emi Inoue-Shinomiya, Sayuri Nitta, Ayako Sato, Yu Asano, Hiroko Nagata, Fukiko Kawai-Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Mamoru Watanabe. A novel culture model for coinfection of hepatitis B and hepatitis C viruses using human induced pluripotent stem cell–derived hepatic cells for analyses of changes in host-innate immune responses . AASLD The Liver Meeting 2017 2017.10.22 Washington DC

33. Miyako Murakawa, Yasuhiro Asahina, Mina Nakagawa, Sayuri Nitta, Fukiko Kawai-Kitahata, Hiroko Nagata, Syun Kaneko, Yu Asano, Masato Miyoshi, Tomoyuki Tsunoda, Emi Inoue-Shinomiya, Ayako Sato, Yasuhiro Itsui, Sei Kakinuma, Seishin Azuma, Mamoru Watanabe. On-treatment higher levels of alpha-fetoprotein and M2BPGi are associated with development of hepatocellular carcinoma during nucleos(t)ide analog therapy in patients with HBV chronic infection. AASLD, The Liver Meeting 2017 2017.10.21 Washington DC

34. Mina Nakagawa, Kumiko Yamaguchi, Janelle Moross, Ayako Ichikawa, Yoko Yoshihashi, Chiharu Kawakami, Jun Tsuruta, Kazuki Takada, Yujiro Tanaka and Junji Tagami. Introduction of interprofessional education (IPE) for medical and dental students. AMEE 2017 2017.08.29 Helsinki

35. Shun Kaneko, Sei Kakinuma, Yasuhiro Asahina, Akihide Kamiya,Masato Miyoshi, Tomoyuki Tsunoda, Sayuri Nitta, Ayako Sato, Yu Asano, Hiroko Nagata, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Mamoru Watanabe. Genetically modified human induced pluripotent stem cell-derived hepatic progenitor-like cell lines as a model for interaction between hepatitis B virus and host cells.. AASLD The Liver meeting 2016 2016.11.11 Boston

36. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Nitta S, Tsunoda T, Miyoshi M, Asano Y, Nagata H , Goto F., Otani S, Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Watanabe M. A new model for studying interaction between hepatitis B virus and host cells derived from human induced pluripotent stem cells.. EASL The International Liver Congress 2016 2016.04.14 Barcelona

37. Nakagawa M. 【HCV 11】Chair. The 25th Asian Pacific Association for the Study of the Liver 2016.02.23 International Convention Center Pamir,Tokyo（JAPAN）

38. Nakagawa M. 【HCV 12】Chair. The 25th Asian Pacific Association for the Study of the Liver 2016.02.23 International Convention Center Pamir,Tokyo（JAPAN）

39. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Nitta S, Tsunoda T, Miyoshi M, Asano Y, Nagata H, Goto F, Otani S, Kitahata F, Murakawa M , Itsui Y, Nakagawa M, Azuma S, Watanabe M. A Model for Interaction between HBV and Host Cells Derived from Human Induced Pluripotent Stem Cells.. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 Tokyo

40. Nakagawa M. 【HCV 】Chair. The 25th Asian Pacific Association for the Study of the Liver 2016.02.22 International Convention Center Pamir,Tokyo（JAPAN）